and CYP2A6 with more similar catalytic efficiencies (k cat /K m 0.19 and 0.12 µM -1 min -1 , respectively) than hydroxylation of the classical substrate coumarin (0.11 and 0.53 µM -1 min -1 , respectively). Of the nine compounds assayed, only tranylcypromine and (R)-(+)-menthofuran had a greater than 10-fold preference for CYP2A6 inhibition versus CYP2A13 inhibition. Most compounds evaluated (tryptamine, 4-dimethylaminobenzaldehyde, phenethyl isothiocyanate, β-nicotyrine, (S)-nicotine, and pilocarpine) demonstrated only moderate or no preference for inhibition of one CYP2A enzyme over the other. However, 8-methoxypsoralen has a 6-fold lower K i for CYP2A13 than for CYP2A6. This information is useful to inform reinterpretation of previous data with these inhibitors and to guide future studies seeking to determine which human CYP2A enzyme is responsible for the in vivo metabolism of compounds in human tissues expressing both enzymes.
This article has not been copyedited and formatted. The final version may differ from this version. compounds are often incubated with microsomes in the presence and absence of potent and selective inhibitors for individual CYP enzymes. This phenotyping process is widely used, but is critically dependent on inhibitor selectivity. Although xenobiotic-metabolizing CYP enzymes have substantial overlapping substrate selectivity, broad efforts have identified sufficiently selective inhibitors for the major human hepatic enzymes, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (reviewed in Khojasteh et al., 2011) .
In extrahepatic tissues, however, discrimination between the roles of individual enzymes is more difficult, both because information about CYP proteins present can be incomplete and selective inhibitors are not as well developed for non-hepatic CYP enzymes. For example, in the human respiratory tract at least 16 CYP enzymes may play a role in the balance between detoxification and activation of environmental pollutants, including industrial chemicals, therapeutic agents, and chemicals in cigarette smoke (reviewed in Pavek and Dvorak, 2008, Zhang et al., 2006) . More than one protein from the same CYP subfamily is often present, further complicating dissection of individual contributions. This is the case for human CYP2A enzymes, CYP2A6 and CYP2A13. Since commercially-available antibodies for these proteins usually cross-react (Su et al., 2000) , information about tissue expression is often derived from mRNA levels. CYP2A13 mRNA is highest in the respiratory tract, but only ~5-and ~9-fold higher than CYP2A6 mRNA in nasal mucosa and lung, respectively (Su et al., 2000) . In contrast, in the liver where CYP2A6 levels are highest, CYP2A6 mRNA is ~1,900-fold higher than CYP2A13. Thus, in human liver microsomes metabolism by and inhibition of CYP2A13 is likely to be negligible, but in respiratory tract microsomes, both CYP2A enzymes may have sequences are 94% identical, and while they have substantial overlapping substrate selectivity, they also have key functional differences (Bao et al., 2005 , Fukami et al., 2008 , Fukami et al., 2007 , Su et al., 2000 . Perhaps the most physiologically relevant is the superior ability of CYP2A13 to activate the tobacco-specific procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Bao et al., 2005 , Su et al., 2000 to diazonium ions that generate DNA adducts and can initiate lung cancer (Hecht, 1998) . However, dissecting the roles of CYP2A enzymes is also likely to be important to evaluate the metabolism of inhaled drugs such as volatile anesthetics or those used for asthma. Thus CYP2A13-and CYP2A6-selective inhibitors are needed to evaluate their respective roles in tissues expressing both enzymes.
A number of compounds have been reported to be selective for CYP2A6 inhibition, but many were evaluated before CYP2A13 was known to be a functional CYP2A enzyme or have simply not been tested with CYP2A13. These include: phenethyl isothiocyante (PEITC), 4-dimethylaminobenzaldehyde (DMABA), 8-methoxypsoralen (8-MOP), tranylcypromine, tryptamine, pilocarpine, (S)-nicotine, (R)-(+)-menthofuran, and β -nicotyrine (Denton et al., 2004 , Khojasteh-Bakht et al., 1998 , Koenigs et al., 1997 , Nakajima et al., 2001 , Rahnasto et al., 2008 , Zhang et al., 2001 . Work conducted to identify potent and selective CYP2A6 inhibitors (Yano et al., 2006) did not evaluate them for their ability to inhibit CYP2A13. Although a few of these inhibitors have now been tested for CYP2A13 inhibition (Bao et al., 2005 , von Weymarn et al., 2006 , von Weymarn et al., 2005 , these studies were conducted using a variety of methods and protein preparations that make comparison of CYP2A inhibition difficult.
Thus, we evaluated the ability of compounds traditionally employed to identify CYP2A6-selective functions for their ability to differentially inhibit CYP2A6 and CYP2A13 using side-by- 
MATERIALS AND METHODS

Chemicals and Reagents
β -nicotyrine was purchased from Toronto Research Chemicals (North York, Canada). Other reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless specified otherwise.
Protein Expression and Purification
Cytochrome P450 2A proteins were expressed in E. coli TOPP-3 cells as a form encompassing truncation of the N-terminal transmembrane helix and addition of a C-terminal four-residue histidine tag as described (DeVore et al., 2008 , Smith et al., 2007 . Transformed colonies were grown in 5 mL cultures in Lysogeny Broth (LB) broth supplemented with ampicillin and tetracycline. Cultures were grown at 37°C for 7-8 hours with shaking (250 rpm). Fifty microliters of the 5 mL culture were used to inoculate 200 mL of LB broth supplemented with ampicillin and tetracycline. Again cultures were grown overnight at 37°C with shaking (250 rpm).
Fifteen milliliters of the overnight culture were used to inoculate 250 mL of Terrific broth supplemented with ampicillin, which was then grown to an OD 600 of 1-1.5 at 37°C while shaking at 250 rpm. Expression was induced by adding isopropyl 7 addition of an equal volume of cold water. After 10 min, the spheroplasts were collected by centrifugation at 10,000 x g for 15 min and the supernatant discarded. The pellet was then frozen using either a liquid nitrogen bath or dry ice/ethanol slurry. Frozen pellets were thawed, suspended in 100 mL of 500 mM potassium phosphate, pH 7.4, containing 20% glycerol, and homogenized by hand. The resulting suspension was sonicated using three 30 sec pulses with 60 sec of cooling on ice between pulses and then centrifuged at 10,000 x g for 15 min. The detergent Cymal-5 (Affymetrix, Maumee, OH) was added to the resulting supernatant to 4.8 mM with stirring. Following centrifugation at 100,000 x g for 60 min., the crude membrane protein sample was purified using a two-step column chromatography scheme. Solubilized protein was first applied to a nickel-nitrilotriacetic acid (Ni-NTA, Qiagen, Valencia, CA) column equilibrated with loading buffer (100 mM potassium phosphate, pH 7.4, 20% glycerol, 0.2 M NaCl, 4.8 mM Cymal-5), and washed with loading buffer followed by wash buffer (100 mM potassium phosphate, pH 7.4, 20% glycerol, 0.2 M NaCl, 4.8 mM Cymal-5, 8 mM histidine). The protein was eluted with 10 mM potassium phosphate, pH 7.4, with 20% glycerol, 0.1 M NaCl, 4.8 mM Cymal-5, 80 mM histidine, and 2 mM EDTA. Fractions with the most P450 (as evaluated by absorbance at 418 nm) were pooled, diluted three-fold with 5 mM potassium phosphate, pH 7.4, with 20% glycerol, 4.8 mM Cymal-5, and 1 mM EDTA, and loaded onto a HiTrap CM-Sepharose Fast Flow column (GE HealthCare, Umeå, Sweden) equilibrated with the same buffer. The CM column was washed with the same buffer without the detergent, and protein eluted with 50 mM potassium phosphate, pH 7.4, with 20% glycerol, 500 mM NaCl, and 1 mM EDTA. Protein was concentrated using centrifugal ultrafiltration. Purification was accomplished at 4 °C and resulted in protein with an A 417 /A 280 of 1.3-1.9 and specific contents of 6.2-14.2 nmol P450/mg protein for various CYP2A6 and CYP2A13 preparations. Enzyme was quantitated using the reduced carbon monoxide difference spectrum as described (Schenkman and Jansson, 2006) . Rat NADPH cytochrome P450 oxidoreductase (Shen et al., 1989) and rat cytochrome b 5 (Holmans et al., 1994) were expressed and purified as described.
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Inhibition Assays
Purified CYP2A protein was reconstituted with NADPH cytochrome P450 reductase and cytochrome b 5 and used to detect pNP and coumarin metabolism in the presence of CYP2A
inhibitors essentially as described (DeVore et al., 2011) with modifications to the mobile phase.
For the pNP assay, the HPLC mobile phase was slightly adjusted to 29% acetonitrile and 0.2% acetic acid and run at 0.8 mL/min, resulting in slight adjustments in retention times (~6 min for 4-NC and ~9 min for pNP). However DMABA required a mobile phase of 26% methanol and 0.2% acetic acid. For both assays the amount of metabolite was determined by comparing the product peak area to a standard curve. Incubations were performed with at least four different inhibitor concentrations and at least eight different substrate concentrations. K i values are the global fit to at least two separate inhibition experiments. The rate of metabolite formation plotted against substrate concentration were initially fit to the Michaelis-Menten equation using GraphPad Prism 5. K m and V max values were determined and used to assess the inhibition mode. The data was then reanalyzed with the appropriate equation for the type of inhibition observed. A selectivity factor indicating preference for CYP2A6 versus CYP2A13 was calculated by taking the ratio of CYP2A13 K i / CYP2A6 K i .
RESULTS
Binding modes and binding affinity
9
The nine CYP2A6 ligands shown in Table 1 were characterized for their binding mode, affinity, and selectivity for both CYP2A enzymes. Difference spectra collected upon ligand titration demonstrated that for both enzymes tranylcypromine, tryptamine, and pilocarpine clearly yielded increases at 431-432 nm and decreases at 406-412 nm typical of type II interactions of nitrogen with the heme iron, as exemplified by tryptamine ( Figure 1A ). CYP2A6
and CYP2A13 binding of the other six ligands caused increases in absorbance at 379-387 nm and decreases at 414-420 nm typical of type I interactions, in which ligand binding disrupts water interaction with the heme iron, as exemplified by (R)-(+)-menthofuran ( Figure 1B ).
Using titrations (e.g. Figure 1A and B) the equilibrium dissociation constants were determined for CYP2A6 and CYP2A13 for each compound (e.g. Figure 1 , insets). Affinities ranged from 0.43 to 54 µM for CYP2A13 and 0.68 to 470 µM for CYP2A6 (Table 1) 
Enzyme inhibition
Compounds were also tested for the ability to inhibit 2-hydroxylation of p-nitrophenol (pNP).
pNP was employed instead of the more traditional CYP2A substrate coumarin because pNP 
DISCUSSION
Spectral ligand binding studies coupled with kinetic analysis for the inhibition of pNP 2-hydroxylation were used to evaluate a chemically diverse set of known CYP2A6 compounds to determine which were able to discriminate effectively between CYP2A6 and CYP2A13 (Table   1) all had similar ~8-fold selectivity for CYP2A13 over CYP2A6 binding to the enzyme resting state, but when inhibition was evaluated, (R)-(+)-menthofuran was one of the more selective inhibitors for CYP2A6, (S)-nicotine and β-nicotyrine showed little selectivity for one enzyme over the other, and 8-MOP retained its selectivity for CYP2A13. Since the contributions of various P450 enzymes to metabolism in tissues are evaluated via inhibition assays, further discussion focuses primarily on the inhibition characteristics to determine which might be useful for distinguishing the individual roles of CYP2A enzymes in tissue samples.
The most selective enzyme inhibitors tested were tranylcypromine and (R)-(+)-menthofuran, which demonstrate a 49-fold and 27-fold preference for CYP2A6 inhibition over CYP2A13, respectively. Tranylcypromine, a monoamine oxidase inhibitor, was a potent inhibitor of CYP2A6 and is commonly used for CYP phenotyping, but the selectivity is less than ideal (Khojasteh et al., 2011) . The K i value of tranylcypromine for CYP2A6 is 16-17 times lower than the next most potently inhibited enzymes found in liver microsomes, CYP2C19 and CYP2E1 (Taavitsainen et al., 2001 ). This is a narrower range than the 49-fold difference in CYP2A6 K i versus CYP2A13 K i reported herein. Thus, although tranylcypromine failed to discriminate very effectively among liver CYP enzymes from other subfamilies, this compound may have somewhat more utility when seeking to discriminate between CYP2A6 and CYP2A13 activities.
Interestingly, tranylcypromine, like tryptamine and pilocarpine, was a type II inhibitor, which are often relatively non-selective among CYP enzymes. This was the case with tryptamine and pilocarpine, but tranylcypromine must have structural features that incorporate some selectivity for CYP2A6 vs. CYP2A13. However, tranylcypromine also had a nanomolar affinity for CYP46A1 in the brain and can strongly inhibit cholesterol 24S-hydroxylase activity (Mast et al., 2010) . This reinforces the idea that care must be taken when selecting an optimal CYP2A
inhibitor depending on the tissue under evaluation. 13 Miyazawa and Haigou, 2011) . Inhibition of pNP 2-hydroxylation herein showed that (R)-(+)-menthofuran was one of the more selective of the traditionally-employed CYP2A6 inhibitors when specifically discriminating enzyme activity within CYP2A family. The observed K i value of 2.0 µM agrees well with 2.5 µM and 0.84 µM reported for CYP2A6 assessed using coumarin hydroxylation and human liver microsomes or purified enzyme (Khojasteh-Bakht et al., 1998) .
Tryptamine and DMABA were only moderately selective for CYP2A6 inhibition. Tryptamine, a precursor to serotonin and melatonin, demonstrated a competitive mode of inhibition for both enzymes. The K i value of tryptamine for CYP2A6 of 1.7 µM was identical to the value previously for CYP2A6-expressing microsomes using coumarin 7-hydroxylase activity (Zhang et al., 2001 ).
The 9.4-fold selectivity for inhibition of CYP2A6 over CYP2A13 is only slightly better than the 4.6-fold selectivity for the mixed mode inhibitor DMABA. Studies using human liver microsomes indicated >20-fold DMABA selectivity for CYP2A6 over all other hepatic cytochrome P450 enzymes, with the exception of CYP2E1 where the DMABA is only 13-fold selective for CYP2A6 (Rahnasto et al., 2008) . , 2001) . A structure of CYP2A6 with 8-MOP (Yano et al., 2005) showed that the exocyclic ketone oxygen is involved in a hydrogen bond with N297. This residue is conserved in the active site of CYP2A13 as well, and has been shown to hydrogen bond with other ligands (DeVore et al., 2008 , Smith et al., 2007 . Thus, the affinity of 8-MOP is likely due, in part to this key interaction. However, other ligands hydrogen bond with N297 yet have lower affinities (coumarin) or bind selectively (phenacetin binds CYP2A13 but not CYP2A6). In these cases the steric contributions of other active site residues serve to substantially modulate binding affinity (DeVore et al., 2008 , DeVore et al., 2009 ). Thus although 8-MOP does not have the highest affinity, it is clearly the most efficient inhibitor of the compounds investigated herein and appears to interact most favorably with CYP2A13 over CYP2A6.
In conclusion, the goal of this study was to compare a set of reportedly CYP2A6-selective compounds to determine their relative ability to discriminate between CYP2A6 and CYP2A13
and thus their utility in distinguishing between CYP2A activities in tissues where both enzymes are present. Tranylcypromine and (R)-(+)-menthofuran were the most selective inhibitors for CYP2A6, with 49-and 27-fold selectivity for CYP2A6 over CYP2A13, respectively. Even though the ability of tranylcypromine to distinguish between CYP2A enzymes is not ideal, this compound can be used as a benchmark for the development of more selective inhibitors. Six of the compounds tested demonstrated only moderate or no real selectivity between the human CYP2A enzymes. Thus, these compounds should not be employed to evaluate individual CYP2A enzyme contributions to metabolism in tissues where both enzymes may be present.
This study did not identify a suitably selective inhibitor for CYP2A13. The 6-fold selectivity of 8-MOP for CYP2A13 over CYP2A6 is marginal at best but provides a starting point for the development of a more selective inhibitor. Altogether, these results can be used as a guide for the selection of CYP2A-selective inhibitors in studies that seek to accurately distinguish between CYP2A6 and CYP2A13 activity. 
TABLES
